乌美溴铵/维兰特罗
组成 | |
---|---|
乌美溴铵 | 毒蕈碱拮抗剂 |
维兰特罗 | 超长效β2激动剂 |
临床资料 | |
商品名 | Anoro Ellipta、Laventair Ellipta |
AHFS/Drugs.com | 专业药物信息 |
核准状况 | |
怀孕分级 |
|
给药途径 | 吸入给药 |
ATC码 | |
法律规范状态 | |
法律规范 |
|
识别信息 | |
CAS号 | 2446159-58-4 |
KEGG |
乌美溴铵/维兰特罗(英语:umeclidinium bromide/vilanterol;商品名:Anoro Ellipta等),是一种用于治疗慢性阻塞性肺病 (COPD) 的固定剂量复方药物。[4][5]它通过吸入给药。
最常见的副作用包括上呼吸道感染、尿路感染、咽炎、鼻窦炎、鼻咽炎、头痛、咳嗽、口咽疼痛、便秘和口干。[3]
2021年,它是美国第212位最常用处方药物,处方数量超过200万张。[6][7]
参考资料
- ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始内容存档于2023-04-10).
- ^ Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC). (emc). 7 October 2019 [29 October 2020]. (原始内容存档于2021-08-29).
- ^ 3.0 3.1 Anoro Ellipta EPAR. European Medicines Agency (EMA). 17 September 2018 [28 October 2020]. (原始内容存档于2020-11-11). Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789.
- ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. 18 December 2013 [2024-03-07]. (原始内容存档于2017-09-24).
- ^ The Top 300 of 2021. ClinCalc. [14 January 2024]. (原始内容存档于15 January 2024).
- ^ Umeclidinium; Vilanterol - Drug Usage Statistics. ClinCalc. [14 January 2024]. (原始内容存档于2024-02-29).
这是一篇关于呼吸系统的药理学小作品。您可以通过编辑或修订扩充其内容。 |